-
In vivo kit
Product Code
ATC code
Marketing Authorisation No.
For preparation of
Active ingredient
Content/vial
Excipients
Indications
Activity for labelling vial
Vials per kit
Recommended doses
Shelf life
Storage
SPC
-
DMSA 1.5 mg
Tc-IK-7
V09CA02
OGYI-T9245/01
Technetium (99mTc) succimer injection
Dimercaptosuccinic acid
1.5 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Calcium gluconate
-
Kidney scintigraphy, static kidney imaging, localisation of the
kidneys with imaging - Determination of the functional mass of the kidney
-
Determination of the relative function ratio (percentage) of the
left and right kidneys
1.0–1.8 GBq
6 injection vials
See in the Summary of Product Charasteristics
24 months
after radiolabelling: 8 h2-8°C
after radiolabelling: ≤ 25°C -
DTPA 9 mg
Tc-IK-8
V09CA01
OGYI-T-9244/01
Technetium (99mTc) pentate injection
Diethylenetriamino pentaacetic acid
9.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Sodium chloride
-
Dynamic studies of kidney, determination of kidney perfusion,
glomerural filtration rate, total and partial kidney function - Examination of the cerebral blood circulation
-
Examination of the gastrointestinal tract by using labelled
foodstuff or drink - Examination of liquor circulation
0.8–2.4 GBq
6 injection vials
See in the Summary of Product Charasteristics
12 months
after radiolabelling: 8 h≤ 25°C
after radiolabelling: ≤ 25°C -
EC 2 mg
Tc-IK-25
V09CAOGYI-T-9141/01
Technetium (99mTc) EC injection
Ethylene-dicysteine
2.0 mg
Vial A- Disodium hydrogen phosphate dihydrate
- Mannitol
- Ascorbic acid
- Sodium edetate
Vial B
- Stannous chloride dihydrate
- Ascorbic acid
- Tartaric acid
Vial C
- Potassium dihydrogen phosphate
- Ascorbic acid
- Dynamic studies of kidney for renal tubular function
0.8–1.6 GBq
3 x 4 injection vials
See in the Summary of Product Charasteristics
12 months
after radiolabelling: 8 h2-8°C
after radiolabelling: ≤ 25°C
-
In vivo kit
Product Code
ATC code
Marketing Authorisation No.
For preparation of
Active ingredient
Content/vial
Excipients
Indications
Activity for labelling vial
Vials per kit
Recommended doses
Shelf life
Storage
SPC
-
PYRON 25 mg
Tc-IK-5
V09BA03
OGYI-T9246/01
Technetium (99mTc) tin pyrophosphate injection
Sodium pyrophosphate
25.0 mg
- Stannous chloride dihydrate
- Sodium chloride
- Bone and acute myocardial infarct scintigraphy
- Blood pool scintigraphy
- Spleen scintigraphy
1.3–3.0 GBq
6 injection vials
See in the Summary of Product Charasteristics
12 months
after radiolabelling: 3 h≤ 25°C
after radiolabelling: ≤ 25°C
-
In vivo kit
Product Code
ATC code
Marketing Authorisation No.
For preparation of
Active ingredient
Content/vial
Excipients
Indications
Activity for labelling vial
Vials per kit
Recommended doses
Shelf life
Storage
SPC
-
MDP 5 mg
Tc-IK-10
V09BA02
OGYI-T9702/01
Technetium (99mTc) medronate injection
Medronic acid
5.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Urea
For bone scintigraphy (diagnostic skeletal imaging)
Use of the preparation is highly recommended for:
- Primer bone tumours
- Metastases of other tumours, for example prostate/breast/lung cancer
- Osteomyelitis
- Metabolic bone diseases
- Paget’s disease
3.0–6.0 GBq
6 injection vials
See in the Summary of Product Charasteristics
12 months
after radiolabelling: 6 h2-8°C
after radiolabelling: ≤ 25°C
-
In vivo kit
Product Code
ATC code
Marketing Authorisation No.
For preparation of
Active ingredient
Content/vial
Excipients
Indications
Activity for labelling vial
Vials per kit
Recommended doses
Shelf life
Storage
SPC
-
MIBITop 1 mg
Tc-IK-81
V09GA01
OGYI-T-23814/01
Technetium (99mTc) sestamibi injection
[tetrakis (1-isocyanide-2-methoxy-2-methylpropyl-)copper(I)] tetrafluoroborate
1.0 mg
- Cysteine hydrochloride monohydrate
- Sodium citrate
- Stannous chloride dihydrate
- D-Mannitol
- Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina
pectoris and myocardial infarction) - Assessment of global ventricular function.First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for
evaluation of left ventricular ejection fraction, volumes and regional wall motion - Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate
or indeterminate - Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in
both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled
to undergo initial surgery of the parathyroid glands.
max. 15.0 GBq
6 injection vials
See in the Summary of Product Charasteristics
24 months
after radiolabelling: 16 h2-8°C
after radiolabelling: ≤ 25°C
-
In vivo kit
Product Code
ATC code
Marketing Authorisation No.
For preparation of
Active ingredient
Content/vial
Excipients
Indications
Activity for labelling vial
Vials per kit
Recommended doses
Shelf life
Storage
SPC
-
FYTON 15 mg
Tc-IK-2
V09DB07
OGYI-T9288/01
Technetium (99mTc) phytate injection
Sodium phytate
15.0 mg
- Stannous chloride dihydrate
- Sodium chloride
- Morphological examination of the liver by imaging technique
- Diagnosis of benign and malignant liver tumours and monitoring of the therapy
- Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct,
etc.)
0.8–1.6 GBq
6 injection vials
See in the Summary of Product Charasteristics
12 months
after radiolabelling: 3 h≤ 25°C
after radiolabelling: ≤ 25°C -
TECHIDA 30 mg
Tc-IK-6
V09DA02
OGYI-T-9210/01
Technetium (99mTc) etifenin injection
Diethyl-acetanilid-imino diacetic acid
30.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Dynamic examination of the function of the hepatocytes
- Liver transplant evaluation
- Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)
- Examination of the acute cholecystitis
- Diagnosis of focalis nodular hyperplasia
0.8–1.6 GBq
6 injection vials
See in the Summary of Product Charasteristics
24 months
after radiolabelling: 6 h2-8°C
after radiolabelling: 2-8°C
Table: I-131 hard capsules for diagnosis and therapy
-
Product name
Product code
ATC code
Marketing Auth. No.
Pharmaceutical Form and Description
Activity per capsule
Radionuclidic purity
Radiochemical purity
Expiry time
Indications and Phosology
Storage
Packaging
-
ThyroTop D 0.5-37 MBq hard capsule complies with the European Pharmacopoeia 0938 monograph
I-RA-7/D
V09F
OGYI-T-9681/05
Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
labelled sodium iodide, for oral administration.0.5-37 MBq
131I ≥ 99.9 %
≥ 95 %
21 days from the manufacturing date
Thyroid diagnostics
- 0.2-0.5 MBq capsule for radioiodine uptake of thyroid in case no accurate dosimetry is
needed. - 2-4 MBq capsule can be used for calculation of personalised dose for the radionuclide
therapy and thyroid scintigraphy for the establishment of the size of the hyperfunctioning
tissue in thyroid nodules. - For whole body radioiodine scintigraphy in differentiated thyroid cancer 37-185 MBq
(usually 74-111 MBq) I-131 is needed. 2-3 capsules should be administered per os.
Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
safety.1-10 capsules in type I injection vial, closed with brombutyl stopper and green aluminium cap in lead
container with paper insert. - 0.2-0.5 MBq capsule for radioiodine uptake of thyroid in case no accurate dosimetry is
-
I-131-sodium-iodide ThyroTop 38-7400 MBq hard capsules complies with the European Pharmacopoeia
2116 monographI-RA-7/K
V10XA01
OGYI-T-9681/01
Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
labelled sodium iodide, for oral administration.38-7400 MBq
131I ≥ 99.9 %
≥ 95 %
21 days from the manufacturing date
Radionuclide therapy
Treatment of hyperthyreosis
- Graves disease.
- Hyperfunctioning adenoma.
- Non immunogenic diffuse goiter.
Treatment of thyroid carcinoma
- Ablation of residual thyroid tissues following thyroid cancer surgery and treatment of
recidivations and metastases. - Required amount of activity is administered per os in one or max. 2 capsules
Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
safety.1 capsule in a plastic insert with screwed cap placed into a lead container with wall thickness of
15-38 mm.
Table: Irradiators
-
OB-SERVO
Classification
IAEA Category
Storage Type
Source Details
Sealed Source
Maximum Activity
Source Type
Source Dimensions
Source Cage Type
Source Cage Capacity
Configuration
Radiation details
Maximum Central Dose Rate
Dose Uniformity (Max)
Dose Rate at 1 m
Accessories
Pressurized Air Supply
Ventilation System
Water Treatment
Safety and Security System
Control System
Electric Requirements
-
IGNIS
Research
Category I.
Dry Storage
Co-60
888 TBq
(24 kCi)CoS-44 HH-N
Ø11×220 mm
Cylindrical
48 pcs
Fixed sources with rotating canister
10 kGy/h
± 20%
–
✓
–
–
✓
✓
50 Hz, 230 V – with ground (Single-Phase Power)
-
SANGUIS
Research
Category I.
Dry Storage
Co-60
444 TBq
(12 kCi)CoS-44 HH-N
CoS-45 HH
CoS-57 HHØ11×220 mm
Ø11×81.5 mm
Ø23.5×36.5 mmCylindrical
8 pcs
Source turn (absorbent unit) and rotating canister
2.5 kGy/h
± 20%
–
–
✓
–
✓
✓
50 Hz, 230 V – with ground (Single-Phase Power)
-
LA/D
Research and Calibration
Category II.
Dry Storage
Co-60
111 TBq
(3 kCi)CoS-57 HH
Ø23.5×36.5 mm
Special Drawer
1 pc
Source hoist with collimator and absorbent unit
–
–
30 Gy/h
✓
–
–
✓
✓
50 Hz, 230 V – with ground (Single-Phase Power)
-
D
Semi – Multipurpose
Category II.
Dry Storage
Co-60
3700 TBq
(100 kCi)CoS-44 HH-N
Ø11×220 mm
Special Drawer
12 pcs
Source hoist with turntable system
–
–
1 kGy/h
✓
✓
–
✓
✓
50 Hz, 230 V – with ground (Single-Phase Power)
-
W
Semi – Multipurpose
Category IV.
Wet Storage
Co-60
7400 TBq
(200 kCi)CoS-43
HH-M
CoS-44 HH-NØ11×451 mm,
Ø11×220 mmCylindrical
20 pcs
Source hoist with turntable system
–
–
1.5 kGy/h
✓
✓
✓
✓
✓
50 Hz, 230 V – with ground (Single-Phase Power)
Table: I-131 MIBG 20 MBq/ml injection for diagnostic use
-
Product code
Pharmaceutical form and description
Activity per vial
Specific activity
Radioactive concentration
Radionuclid impurities
Radiochemical purity
pH
Expiry date
Indications and posology
Recommended dose
Storage
Packaging
-
I-RAO-1
Radioactive sterile injection solution.
The active ingredient of the radioactive solution for
injection for intravenous use is I-131 radioisotope labelled meta-iodobenzyl-guanidine (MIBG).20 MBq, 40 MBq, or 80 MBq at activity reference date and time
≥ 26.7 GBq/g MIBG at activity reference date and time
20 MBq/ml at activity reference date and time
≤ 0.1%
≥ 95%
5–7
5 days from manufacturing date
Indication field: radioisotope diagnostics
Localisation and imaging of neuroendocrine tumours, especially:phaeochromocytomaneuroblastomaThe recommended individual patient dose is 20–40 MBq I-131-MIBG
To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
before the examination. The injection should be administered slowly; time of administration is 2-4
minutes.Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
asthmatic spasms.Store in refrigerator at 2–8°C. Comply with the regulations for radiation safety.
In type I injection vial (6R) closed with brombutyl stopper and green aluminium cap in lead container
with paper insert.Transported in a Type A package
Table: I-131 MIBG 370 MBq/ml injection for therapy
-
Product code
Pharmaceutical form and description
Activity per vial
Specific activity
Radioactive concentration
Radionuclid impurities
Radiochemical purity
pH
Expiry date
Indications and posology
Recommended dose
Storage
Packaging
-
I-RAO-2
Radioactive sterile solution for injection.
For intravenous use. The active ingredient of the radioactive solution for injection for intravenous
use is I-131 radioisotope labelled meta-iodobenzylguanidine (MIBG)3300-4100 MBq at activity reference date and time
≥ 555 GBq/g at activity reference date and time
333-410 MBq/ml at activity reference date and time
≤ 0.1%
≥ 90%
5-5.5
5 days from manufacturing date
RADIOISOTOPE THERAPY
Local, lesion-specific treatment of neuro-endocrine tumours, especially:
- phaeochromocytoma
- neuroblastoma
- paraganglioma
- medullar thyroid carcinoma
- carcinoid
The recommended individual dose is 3.3–4.1 GBq.
To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
before the examination.Do not administer the injection directly. 10 ml of the MIBG solution for injection must be mixed with
90 ml of 5% glucose injection. The obtained solution which has a total volume of 100 ml should be
administered to the patient slowly. Time of administration is 2 – 4 hours.Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
asthmatic spasms.Store in a freezer, below -18°C. Storage of radiopharmaceuticals should be in accordance with
national regulation on radioactive material. To ensure the low temperature during shipping dry-ice
is used to cool the container.In type I injection vial (10R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert.Transported in a Type A package
Table: I-131 sodium iodide solutions, drug substances supported with Active Substance Master File
-
Product name
Product code
Description
Volume
Radioactive concentration
Radionuclidic purity
Radiochemical purity
pH
Expiry time
Other information
Storage
Packaging
-
I-131 sodium iodide sterile solution, drug substance according to European Pharmacopoeia 0281
monographI-RA-7
Clear, colourless and sterile solution of 131I sodium iodide containing iodine-131 in the form of
sodium idoide in Na2CO3/NaHCO3/NaOH buffer and 0.5-2 mg/ml sodium thiosulphate solution, reducing
agent diluted accoring to the cusomer specified active concentration. Bacterial endotoxins <100
IU/ml.Non-carrier added
0.2 – 10.0 ml
0.1 – 55.5 GBq/ml
131I ≥ 99.9 %
≥ 95 %
7 – 10
21 days from manufacturing date
Active pharmaceutical ingredient for manufacture of radiopharmaceuticals by dilution with water or by
for capsule preparation.For oral administration.
Store at room temperature in its own container, in accordance with the regulations on radioactive
materials.In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert (Type A packaging).Pack size: ≤ 29.6 GBq (at the indicated calibration date)/vial
-
I-131 sodium iodide non-sterile solution, drug substance for radiolabelling according to European
Pharmacopoeia 02121 monographI-RA-5
Clear, colourless and non-sterile solution of 131I sodium iodide containing iodine-131 in the form of
sodium iodide in Na2CO3/NaHCO3/NaOH buffer diluted with 0.0001M NaOH according to the customer
specified active concentration.Non-carrier added. No reducing agents added.
0.2 – 10.0 ml
≥ 0.1-55.5 GBq/ml
131I ≥ 99.9 %
≥ 95 %
8 – 11
21 days from manufacturing date
Active ingredient for manufacture of radiopharmaceuticals by dilution – e.g. with water or buffer for
labelling purposes or capsule preparation, for oral administration.Store at room temperature in its own container, in accordance with the regulations on radioactive
materials.In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert (Type A packaging).Pack size: ≤ 111 GBq (at the indicated calibration date)/vial
Table: I-125 Radiochemicals
-
Product code
Description
Specific activity
Radioactive concentration
Radionuclid impurities
Radiochemical purity
pH
Calibration date
Expiry date
Storage
Packaging
-
I-RB-4
Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added
≥ 600 GBq/mg
≤ 3669 MBq/ml
I-126 ≥ 0.005%
≥ 95%
8 – 11
13 days
60 days from dispatch
Store at room temperature in its own container, in accordance with the regulations on radioactive materials.
Supplied in plastic vial placed in a lead container (KT 1-3).
The lead container is packed in a labelled easy-open metal can, which contains plastic insert.
Transported in a Type A packaging in accordance with IATA regulation.
-
I-RB-41
Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added
≥ 600 GBq/mg
≥ 3700 MBq/ml
I-126 ≥ 0.005%
≥ 95%
8 – 11
13 days
60 days from dispatch
Store at room temperature in its own container, in accordance with the regulations on radioactive materials.
Supplied in plastic vial placed in a lead container (KT 1-3).
The lead container is packed in a labelled easy-open metal can, which contains plastic insert.
Transported in a Type A packaging in accordance with IATA regulation.
Table: Distributed Products
-
SPECIFICATIONS
Standards
Density Measurement Range
Moisture Measurement Range
Density Source
Moisture Source
Density Source Activity
Moisture Source Activity
PRECISION
BS one-minute test
Transmission one-minute test
Moisture one-minute test
CHEMICAL COMPOSITION ERROR
Backscatter
Transmission
SURFACE ROUGHNESS ERROR (0.05 in. 100% void)
Backscatter
Transmission
OPERATING TEMPERATURE
Ambient
Surface
Power Source
Battery Life
Display
Memory Storage
Gauge Size
Weight
Shipping Weight
-
ASTM D6938, D2950, D7013, D7759, C1040 and AASHTO T310
70 to 170 pcf
(1.120 to 2.73 gcc)0 to 40 pcf (0 to 0.64 gcc)
Cesium 137
Americium 241: Beryllium
Maximum (10 mCi) 370 Mbq
Maximum (50 mCi) 1.85 GBq
±0.50 pcf (0.008 gcc)(at 125 pcf)
±0.25 pcf (0.004 gcc)(at 125 pcf)
±0.25 pcf (0.004 gcc)(at 10 pcf)
±1.00 pcf (0.016 gcc)
±0.75 pcf (0.012 gcc)
– 4.00 pcf (0.064 gcc)
– 0.50 pcf (0.008 gcc)
– 14° to 167°F (-10° to 75°C)
Up to 350°F (175°C)
6-Cell AA NiMH battery pack with a single 9V alkaline for backup
500-1000 recharge/discharge cycles
Large 4 line X 20 character LCD display with 9mm tall characters
10 Projects with 40 readings each
26.7″ H X 14.1″ W X 9.8″ D
(67.8 x 35.8 x 24.8 cm)28.5 lbs (13 kg)
90 lbs (40.82 kg)
Table: Immunoassay – Tumour Markers
-
Product code
Product name
Pack size (Test)
IFU/
EN IFU/
ES IFU/
RU
-
RK-800CT
AFP [I-125] IRMA KIT
[100]
-
RK-760CT
ßhCG [I-125] IRMA KIT
[100]
-
RK-820CT
free ßhCG [I-125] IRMA KIT
[100]
-
RK-38CT
hCEA [I-125] IRMA KIT
[100]
-
RK-10CT
hPSA [I-125] IRMA KIT
[100]
-
RK-85CT
free PSA [I-125] IRMA KIT
[100]
-
RK-125CT
CA125 [I-125] IRMA KIT
[100]
-
RK-199CT
CA 19-9 [I-125] IRMA KIT
[100]
-
RK-153CT
CA 15-3 [I-125] IRMA KIT
[100]
-
RK-724CT
CA 72-4 [I-125] IRMA KIT
[100]
-
RK-211CT
CYFRA 21.1 IRMA KIT
[100]
-
RK-300CT
NSE [I-125] IRMA kit *
[100]
* =on request product / minimum order: 5 kits
Table: Immunoassay – Diabetes
-
Product code
Product name
Pack size (Test)
IFU/
EN IFU/
ES IFU/
RU
-
RK-84CT
hC-peptide [I-125] IRMA KIT
[100]
-
RK-400CT
INSULIN [I-125] IRMA KIT
[100]
-
RK-20P100
Anti-IA2 RIA KIT
[100]
-
RK-40P100
Anti-GAD65 RIA KIT
[100]
-
RK-50P100
IAA RIA KIT
[100]
-
RK-20P50
Anti-IA2 RIA KIT
[50]
-
RK-40P50
Anti-GAD65 RIA KIT
[50]
-
RK-50P50
IAA RIA KIT
[50]
Table: Immunoassay – Thyroid Functions
-
Product code
Product name
Pack size (Test)
IFU/
EN IFU/
ES IFU/
RU
-
RK-83CT
hCalcitonin [I-125] IRMA KIT
[100]
-
RK-8CT
Anti-hTG [I-125] RIA KIT
[100]
-
RK-51CT
hTG [I-125] IRMA KIT
[100]
-
RK-36CT
Anti-hTPO [I-125] RIA KIT
[100]
-
RK-1CT1
Turbo TSH [I-125] IRMA KIT
[100]
-
RK-1CT5
Turbo TSH [I-125] IRMA KIT
[500]
-
RK-339CT
FT3 [I-125] RIA KIT
[100]
-
RK-349CT
FT4 [I-125] RIA KIT
[100]
-
RK-11CT1
T4 [I-125] RIA KIT
[100]
-
RK-609CT
T3 [I-125] RIA KIT
[100]
-
RK-950CT
T3 UPTAKE [I-125] RIA KIT
[100]
Table: Immunoassay – Steroid Hormones
-
Product code
Product name
Pack size (Test)
IFU/
EN IFU/
ES IFU/
RU
-
RK-460CT
PROGESTERONE [I-125] RIA KIT
[100]
-
RK-61CT
TESTOSTERONE [I-125] RIA KIT
[100]
-
RK-240CT
CORTISOL [I-125] RIA KIT
[100]
-
RK-620CT
DHEA-SO4 [I-125] RIA KIT
[100]
Table: Immunoassay – Serum Proteins
-
Product code
Product name
Pack size (Test)
IFU/
EN IFU/
ES IFU/
RU
-
RK-5CT
hGH [I-125] IRMA KIT
[100]
-
RK-750CT
hLH [I-125] IRMA KIT
[100]
-
RK-780CT
hPRL [I-125] IRMA KIT
[100]
-
RK-790CT
hFSH [I-125] IRMA KIT
[100]
-
RK-4CT
PAPP-A [I-125] IRMA kit
[100]
-
RK-86CT
SHBG [I-125] IRMA KIT
[100]
-
RK-900CT
FERRITIN [I-125] IRMA KIT
[100]
Table: Radiation Protection Systems – HK Marked Group of Products
-
Sign
Activity of the
Transportable Material (Co-60)
[GBq]Inner Size of the
Storage Unit
[mm]Weight of Package
Container/Package/ Gross
[kg]
-
HK-5
5
50 x 50
70/145/215
-
HK-10
10
50 x 150
230/140/370
-
HK-40
40
50 x 150
420/140/560
-
HK-400
400
80 x 150
640/135/775
Table: Other Labelled Products – Carbon-14
-
Code
Product
specific activity: 370 – 1850 MBq /mmolUnlabelled
CAS number
-
CC-502
N-Acetyl-2-chloro-[U-14C]aniline
533-17-5
-
CC-501
N-Acetyl-2-nitro-[U-14C]aniline
552-32-9
-
CC-509
[U-14]Benzenesulfonyl chloride
98-09-9
-
CC-563
1,3-Bis(4-nitro-[U-14]phenyl)urea; DNC, [ring-U-14]
587-90-6
-
CC-566
4-Bromo-N,N-dimethyl-[U-14C]aniline
586-77-6
-
CC-528
i-[1-14C]Butyric acid hydrazide
3619-17-8
-
CC-543
4-Chloro-[ring-U-14C]benzoic acid
74-11-3
-
CC-439
Copper(I) [14C]cyanide
544-92-3
-
CC-591
[2-14C]Cyclohexane-1,3-dione
504-02-9
-
CC-590
3,4-Dichloro-[U-14C]aniline
95-76-1
-
CC-507
2,4′-Dichloro-[carbonyl-14C]benzophenone
85-29-0
-
CC-511
2,4′-Dichloro-[4′-chlorophenyl-U-14C]benzophenone
85-29-0
-
CC-592
[1,2-14C]Dichloroethane
107-06-2
-
CC-521
2,5-Dichloro-[U-14C]phenol
583-78-8
-
CC-506
3,4-Dimethyl-[U-14C]aniline
95-64-7
-
CC-520
4-Fluoro-[ring-U-14C]acetanilide
351-83-7
-
CC-564
2-Hydroxy-4,6-dimethyl-[2-14C]pyrimidine; HDP, [2-14C]
108-79-2
-
CC-595
4-Iodo-nitro[U-14C]benzene
636-98-6
-
CC-508
[2-14C]Isopropyl-triphenyl-phosphonium iodide
24470-78-8
-
CC-515
Medetomidine, [imidazole-2-14C]
86347-14-0
-
CC-517
Medetomidine, [phenyl U-14C]
86347-14-0
-
CC-561
4-Methyl-[ring-U-14C]acetophenone
122-00-9
-
CC-513
Methyl 2-pyrimidine[14C]carboxylate
34253-03-7
-
CC-519
[carboxyl-14C]Nicotinic acid
59-67-6
-
CC-594
2-Nitro-[U-14C]aniline
88-74-4
-
CC-518
4-Nitro-[U-14C]aniline
100-01-6
-
CC-505
4-Nitro-[formyl-14C]benzaldehyde
555-16-8
-
CC-18
4-Nitro-[U-14C]phenol
100-02-7
-
CC-237
Phenyl-[1-14C]acetic acid
103-82-2
-
CC-471
2-Phenyl-[1-14C]propionic acid
492-37-5
-
CC-461
2-[ring-U-14C]Phenylpropionic acid
492-37-5
-
CC-510
Potassium [14C]thiocyanate
333-20-0
-
CC-523
Sulfadiazine, [phenyl ring-U-14C]
68-35-9
-
CC-476
Sulfamethoxazole, [phenyl ring-U-14C]
723-46-6
-
CC-195
[1,4-14C]Succinic acid
110-15-6
-
CC-468
Tilmicosin, [3,5-dimethylpiperidin-1-yl-3,5-14C]
108050-54-0
-
CC-522
4-[ring-U-14C]Toluic acid
99-94-5
-
CC-495
1,2,4-Trichloro-[U-14C]benzene
120-82-1
-
CC-553
Triethyl phosphono[1-14C]acetate
867-13-0
-
CC-499
2-Trifluoromethyl-[ring-U-14C]benzoic acid
433-97-6
-
CC-361
Troglitazone, [thiazolidin-2,4-dione 2-14C]
97322-87-7
-
CC-426
Zinc [14C]cyanide
557-21-1
Table: Research immunoassay kits – Rat Hormones
-
Code
Test
Pack Size (Tests)
IFU
-
RK-547
rInsulin RIA kit *
120
-
RK-547CT
rInsulin IRMA kit coated tube version
100
-
EK-547
rInsulin ELISA kit
96
-
RK-548
rCorticosterone RIA kit
120
-
RK-548CT
rCorticosterone RIA kit coated tube version
100
-
EK-548
rCorticosterone ELISA kit
96
-
RK-550
rFSH (rat follicle stimulating hormone) RIA kit
120
-
RK-551
rGH (rat growth hormone) RIA kit
120
-
RK-552
rLH (rat luteinizing hormone) RIA kit
120
-
RK-553
rPRL (rat prolactin) RIA kit*
120
-
RK-554
rTSH (rat thyroid stimulating hormone) RIA kit
120
-
RK-554Cset
rTSH (rat thyroid stimulating hormone) RIA kit Control set
–
-
EK-547Cset
rInsulin ELISA kit Control set
–
*On request
List of scientific publications HERE
Table: Research immunoassay kits – Human Research Kits
-
Code
Test
Pack Size (Tests)
IFU
-
RK-509
cAMP (adenosine 3′,5′-cyclic monophosphate) RIA kit*
100
-
RK-512
αANP (human α-atrial natriuretic peptide) RIA kit *
100
-
RK-518
C3a (human complement C3a des Arg) RIA kit
150
-
RK-518Cset
C3a (human complement C3a des Arg) RIA kit Control set
-
RK-519
C4a (human complement C4a des Arg) RIA kit
150
-
RK-519Cset
C4a (human complement C4a des Arg) RIA kit Conrol set
-
RK-520
C5a (human complement C5a des Arg) RIA kit
150
-
RK-525
cGMP (guanosine 3′,5′-cyclic monophosphate) RIA kit*
100
-
RK-535
Endothelin-1,2 RIA kit *
100
-
RK-545
Endothelin-1,2 high sensitivity RIA kit *
100
-
RK-555
Endothelin 1-21 RIA kit *
100
* On request
Table: Research immunoassay kits – Human IVD kits useful for Animal Science Research
-
Bovine
Ovine
Caprine
Equine
Porcine
Rabbit
Rodents
Poultry
Monkey
Fish
-
Thyroid hormones
RK-609CT, RK-339CT, RK-11CT1, RK-349CT
-
Progesterone
RK-460CT
-
Testosterone
RK-61CT
-
Cortisol
RK-240CT